Header Ads Widget

Below Post Ad

Glenmark Life Sciences IPO Review

 

Glenmark Life Sciences Logo
Glenmark Life Sciences IPO Date, Review, Price, Form & Market Lot Details


Glenmark Life Sciences IPO to hit the market on 27 July 2021 as per the RHP filed on 19 July 2021. The company to raise ₹1514 crores via initial public offer with a face value of ₹2 per equity share. The IPO comprises fresh issue of 1060 crores and offer for sale of 6,300,000 equity shares of Glennmark Pharmceuticals Limited .
 
Glenmark Life Sciences IPO to hit the market on 27 July 2021 and closes on 29 July 2021. The company plans to raise ₹1514 crore through the initial public offerings. Glenmark Life Sciences is an API arm of Glenn Mark Pharma, a leading drug maker. They are one of the leading developer and manufacturer of Active Pharmaceutical Ingredients (APIs). They are making high-quality drugs by unlocking the possibilities of science. They created the strong relationship with leading pharmaceutical companies that have helped us expand our product offerings and geographic reach. They have 120 API in their catalogue. They supply their API to 540 pharma companies in India and overseas. They export their products in Europe, Latin America, North America, Japan, and the rest of the world. Check out Glenmark Life Sciences IPO details.

Important Details:
According to the DRHP, the proceeds from the IPO will be used for:
  • Payment of outstanding purchase consideration to the promoter for the spin-off of the API businessb)
  •  Funding capital expenditure requirements
  • General corporate purposes
  • Listed Industry Peer Group:
  • Divis Laboratories
  • Laurus Labs
  • Shilpa Medicare
  • Aarti Drugs
  • Solara Active Pharma Sciences

Post a Comment

0 Comments